Development of Teneligliptin Polymeric Nanocarriers for Antidiabetic Therapy: Formulation and Evaluation

The present study focuses on the formulation and evaluation of Teneligliptin-loaded nanoparticles by using the nanoprecipitation method to enhance the solubility of teneligliptin and therapeutic efficacy in the management of Type 2 Diabetes Mellitus. The nanoparticle prepared by using ethyl cellulose and polyvinyl alcohol was employed as polymer and stabilizer, respectively, to prepare nine different batches F1 to F9 were prepared. The nanoparticles were characterized for total drug content, entrapment efficiency, particle size, zeta potential, surface morphology, FT-IR, DSC and XRD study. Drug content among the formulations ranged from 90.94 % to 99.06 %, and entrapment efficiency varied between 93.95 % and 99.17 %. Particle size analysis revealed a range of 194.80 nm to 268.50 nm, while zeta potential values spanned from −11.25 mV to −26.90 mV, indicating good colloidal stability. In vitro drug release studies conducted over 60 minutes showed cumulative release ranging from 44.18 % to 76.74 %. Batch F7 shows excellent results optimal characteristics, including the highest drug content (99.06 %), entrapment efficiency (99.17 %), and favourable particle size distribution. In vitro drug release studies revealed that F7 exhibited the maximum cumulative drug release (76.74 % at 60 minutes), following Korsmeyer–Peppas kinetics indicative of anomalous (non-Fickian) diffusion. These findings suggest that Teneligliptin nanoparticles, particularly formulation F7, offer a promising approach for improved drug delivery and bioavailability in diabetic therapy.